Sofinnova News
Video: Sofinnova Partners 2024 annual general meeting
Related Strategy
CapitalRelated Strategy
CrossoverRelated Strategy
MD StartRelated Strategy
Digital MedicineRelated Strategy
Industrial BiotechRelated Strategy
TelethonRelated Strategy
BiovelocitaOur Annual General Meeting is a pivotal event that underscores the importance of collaboration and innovation in navigating our changing world, particularly in the current climate.
During this year's two-day event, our LPs, investment teams, and the CEOs of our portfolio companies shared stories of passion, perseverance, and the relentless pursuit of innovation to improve the health of people and the planet. These highlights remind us of the fundamentals we uphold in this period of constant change and uncertainty.
We extend our deepest gratitude to our LPs for their unwavering trust and support throughout the years. Their belief in our mission enables us to continue investing in groundbreaking science and innovation, which are essential in addressing our ever-changing world.
Check-out the video to get a glimpse of our 2024 Annual General Meeting:
Video of Sofinnova Partners 2024 Annual General Meeting
Related News
Bionyra Pharma Announces First Healthy Volunteers Dosed in Phase 1 Study of BYN-001, a Long-Acting IL-25 Antibody for Atopic Dermatitis
NodThera Inc. Changes Name to Rezera Inc. and Announces Ruvonoflast Phase 3 Development Program
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
Rezera Announces Ruvonoflast Met its Primary Inflammation Endpoint and Demonstrated Favorable Safety Profile in RESOLVE-1 Phase 2 Clinical Trial
Neurent Medical Secures €25 Million Growth Debt Facility from Claret Capital Partners to Accelerate Commercial Expansion